We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
Read MoreHide Full Article
Cencora, Inc. (COR - Free Report) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 6.6% year to date compared with the industry’s 3.4% growth. The S&P 500 Index has risen 11.6% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies, focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $43.66 billion.
COR’s bottom line is anticipated to improve 10.7% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.12%.
Image Source: Zacks Investment Research
What’s Driving Growth?
COR currently reports under two segments — U.S. Healthcare Solutions and International Healthcare Solutions.
The first segment comprises the legacy Pharmaceutical Distribution Services (excluding Proforma), MWI Animal Health, Xcenda, Lash Group and ICS 3PL. It benefits from an increasing volume and expanding customer base.
Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to medical care, enhanced economic conditions and population demographics are likely to favor the segment in the upcoming quarters.
In the second quarter of fiscal 2024, revenues at U.S. Healthcare Solutions totaled $61.3 billion, up 8.1% year over year. The company continues to witness a strong segmental performance due to growth in all markets and strong demand for specialty products, especially GLP-1 drugs. High demand for the recently approved GLP-1 drugs for diabetes and/or weight loss is likely to continue going forward.
Segmental operating income amounted to $841.1 million, up 11.2% year over year. Higher gross profit (including fees earned from the distribution of government-owned COVID-19 treatments and a gross profit on sales from specialty physician practices) contributed to the upside.
Revenues at the U.S. Healthcare Solutions segment are expected to grow 11-13% for fiscal 2024. Operating income is anticipated to increase 10-12% during the same time frame.
Also, Cencora is expected to benefit from generics growth in the long run, raising investors’ optimism. It is well-positioned to help ensure the smooth entry of its products into the market. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to care, better economic conditions and population demographics, introduction of new innovative drugs like hepatitis C drugs and a continued good brand pricing environment should aid. Moreover, the company’s focus on specialty drugs bodes well.
Adjusted earnings per share for fiscal 2024 are estimated between $13.30 and $13.50, implying a 10.5-12.6% increase from the previous year’s level. COR estimates revenues to grow 10-12% year over year. Total adjusted operating income is expected to improve 9-11% during the same time frame.
What’s Hurting the Stock?
Cencora operates in a highly competitive pharmaceutical distribution and related healthcare services market. The generic industry is facing consolidation of customers and manufacturers, global competitors and regulatory challenges.
The company encounters additional competition from manufacturers, chain drugstores, specialty distributors, and packaging and healthcare technology companies. The increasing competition is likely to affect its business.
Estimate Trend
COR has been witnessing a positive estimate revision trend for fiscal 2024. In the past 30 days, the Zacks Consensus Estimate for earnings has increased from $13.43 per share to $13.44.
The consensus mark for second-quarter fiscal 2024 revenues is pegged at $73.57 billion, indicating a 9.9% improvement from the year-ago quarter’s reported actuals. The bottom-line estimate is pinned at $3.19, implying year-over-year growth of 9.3%.
Some better-ranked stocks in the broader medical space areDaVita Inc. (DVA - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Ecolab Inc. (ECL - Free Report) .
DaVita, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 29.35%. You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have risen 32.2% year to date compared with the industry’s 8.7% growth.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.49%.
Boston Scientific’s shares have risen 30.9% year to date compared with the industry’s 3% growth.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.3%.
Ecolab’s shares have rallied 18.1% year to date against the industry’s 19.7%decline.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
Cencora, Inc. (COR - Free Report) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 6.6% year to date compared with the industry’s 3.4% growth. The S&P 500 Index has risen 11.6% in the same time frame.
Cencora is one of the world’s largest pharmaceutical service companies, focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $43.66 billion.
COR’s bottom line is anticipated to improve 10.7% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.12%.
Image Source: Zacks Investment Research
What’s Driving Growth?
COR currently reports under two segments — U.S. Healthcare Solutions and International Healthcare Solutions.
The first segment comprises the legacy Pharmaceutical Distribution Services (excluding Proforma), MWI Animal Health, Xcenda, Lash Group and ICS 3PL. It benefits from an increasing volume and expanding customer base.
Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to medical care, enhanced economic conditions and population demographics are likely to favor the segment in the upcoming quarters.
In the second quarter of fiscal 2024, revenues at U.S. Healthcare Solutions totaled $61.3 billion, up 8.1% year over year. The company continues to witness a strong segmental performance due to growth in all markets and strong demand for specialty products, especially GLP-1 drugs. High demand for the recently approved GLP-1 drugs for diabetes and/or weight loss is likely to continue going forward.
Segmental operating income amounted to $841.1 million, up 11.2% year over year. Higher gross profit (including fees earned from the distribution of government-owned COVID-19 treatments and a gross profit on sales from specialty physician practices) contributed to the upside.
Revenues at the U.S. Healthcare Solutions segment are expected to grow 11-13% for fiscal 2024. Operating income is anticipated to increase 10-12% during the same time frame.
Also, Cencora is expected to benefit from generics growth in the long run, raising investors’ optimism. It is well-positioned to help ensure the smooth entry of its products into the market. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to care, better economic conditions and population demographics, introduction of new innovative drugs like hepatitis C drugs and a continued good brand pricing environment should aid. Moreover, the company’s focus on specialty drugs bodes well.
Adjusted earnings per share for fiscal 2024 are estimated between $13.30 and $13.50, implying a 10.5-12.6% increase from the previous year’s level. COR estimates revenues to grow 10-12% year over year. Total adjusted operating income is expected to improve 9-11% during the same time frame.
What’s Hurting the Stock?
Cencora operates in a highly competitive pharmaceutical distribution and related healthcare services market. The generic industry is facing consolidation of customers and manufacturers, global competitors and regulatory challenges.
The company encounters additional competition from manufacturers, chain drugstores, specialty distributors, and packaging and healthcare technology companies. The increasing competition is likely to affect its business.
Estimate Trend
COR has been witnessing a positive estimate revision trend for fiscal 2024. In the past 30 days, the Zacks Consensus Estimate for earnings has increased from $13.43 per share to $13.44.
The consensus mark for second-quarter fiscal 2024 revenues is pegged at $73.57 billion, indicating a 9.9% improvement from the year-ago quarter’s reported actuals. The bottom-line estimate is pinned at $3.19, implying year-over-year growth of 9.3%.
Cencora, Inc. Price
Cencora, Inc. price | Cencora, Inc. Quote
Key Picks
Some better-ranked stocks in the broader medical space areDaVita Inc. (DVA - Free Report) , Boston Scientific Corporation (BSX - Free Report) and Ecolab Inc. (ECL - Free Report) .
DaVita, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 29.35%. You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have risen 32.2% year to date compared with the industry’s 8.7% growth.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.49%.
Boston Scientific’s shares have risen 30.9% year to date compared with the industry’s 3% growth.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.3%.
Ecolab’s shares have rallied 18.1% year to date against the industry’s 19.7%decline.